EUVIMEDEUVIMED entdecken
Kommentar

Has APOL1 kidney disease treatment been hiding in plain sight?

Opeyemi A Olabisi

Kidney International · 2024

DOI: 10.1016/j.kint.2024.09.003 ↗

Kurz gefasst

Kommentar in der Zeitschrift Kidney International, 2024. Verfasst von Opeyemi A Olabisi. Beteiligte Einrichtung: Department of Medicine, Division of Nephrology and Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina, U…. Hauptthemen laut MEDLINE: Apolipoprotein L1, Glomerulosclerosis, Focal Segmental, Angiotensin-Converting Enzyme Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Two coding variants of APOL1 account for much of the excess risk of focal segmental glomerulosclerosis in people of recent West African ancestry. There is an unmet need of treatment for apolipoprotein L1 kidney disease. In this issue, Sula Karreci et al. reported that lisinopril reduced proteinuria and glomerulosclerosis in a mouse model of apolipoprotein L1-induced focal segmental glomerulosclerosis, in a genotype-specific manner. By contrast, hydralazine and dapagliflozin had no effect. This study highlights the potential therapeutic utility of angiotensin-converting enzyme inhibitor in apolipoprotein L1 kidney disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Apolipoprotein L1Glomerulosclerosis, Focal SegmentalAngiotensin-Converting Enzyme InhibitorsAnimalsHumansMiceLisinoprilDisease Models, AnimalApolipoproteinsProteinuriaLipoproteins, HDL

Substanzen

Apolipoprotein L1APOL1 protein, humanAngiotensin-Converting Enzyme InhibitorsLisinoprilApolipoproteinsLipoproteins, HDL

Autor:innen und Institutionen

  • Department of Medicine, Division of Nephrology and Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina, USA. Electronic address: Opeyemi.olabisi@duke.edu.

Zitieren

APA

Olabisi, O. A. (2024). Has APOL1 kidney disease treatment been hiding in plain sight?. Kidney International. https://doi.org/10.1016/j.kint.2024.09.003

Vancouver

Olabisi OA. Has APOL1 kidney disease treatment been hiding in plain sight?. Kidney International. 2024. doi:10.1016/j.kint.2024.09.003

BibTeX
@article{Olabisi2024,
  author = {Olabisi, Opeyemi A},
  title = {Has APOL1 kidney disease treatment been hiding in plain sight?},
  journal = {Kidney International},
  year = {2024},
  doi = {10.1016/j.kint.2024.09.003}
}
Kostenlos starten →